{
    "nctId": "NCT06363123",
    "briefTitle": "Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis",
    "officialTitle": "Identification and Validation of Plasma Diagnostic Biomarkers for Multi-Cancer Based on Metabolomics: A Multi-Center Clinical Research and Validation Trial",
    "overallStatus": "RECRUITING",
    "conditions": "Lung Cancer, Breast Cancer, Colorectal Cancer, Thyroid Cancer, Gastric Cancer, Cervical Cancer, Liver Cancer, Pancreatic Cancer, Cholangiocarcinoma, Prostate Cancer, Esophageal Cancer, Ovarian Cancer, Renal Cell Carcinoma",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 2700,
    "primaryOutcomeMeasure": "Plasma metabolite content",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Multi-Cancer Group:\n\n  * Patients with a confirmed diagnosis based on the clinical \"gold standard\".\n  * Collection of plasma samples prior to treatment.\n  * Availability of complete clinical data.\n* Control Group:\n\n  * Individuals with no abnormalities in routine physical examinations and relevant clinical tests.\n  * Age \u2265 45 years.\n  * Availability of complete clinical data.\n\nExclusion Criteria:\n\n* Previous reception of anti-tumor treatments (including radiotherapy, chemotherapy, etc.) before blood collection.\n* Coexistence of other systemic tumors.\n* Absence of plasma sample collection before treatment.\n* Pregnancy status.\n* No clear evidence of histopathological diagnosis (not applicable to the control group based on this criterion).\n* Patients with severe acute infections.\n* Patients with severe anemia.\n* Patients with severe liver or kidney dysfunction.\n* Patients with autoimmune deficiency diseases.\n* Patients with Hyperlipidemia.\n* Patients received contrast agent injection before blood draw.\n* Patients with psychiatric disorders.",
    "sex": "ALL",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}